Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiae469 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Sunwen Chou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Drug Resistance, Viral, Antiviral Agents, Cytomegalovirus Infections, Ribonucleosides. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc, VA, US.
Abstract (Originalsprache)
Background
Among 547 patients receiving maribavir or valganciclovir for first-episode cytomegalovirus infection after hematopoietic cell transplant, the treatment response rate was 69.6% and 77.4% respectively. Development of maribavir and ganciclovir resistance was compared after receiving either drug.
Methods
Viral mutations conferring drug resistance were analyzed in plasma DNA extracts at baseline and posttreatment.
Results
Prior antiviral drug exposure was limited, with only 2 instances of baseline drug resistance detected. An equal number (n = 241) received valganciclovir or maribavir for at least 21 days (median, 55–56 days). Among them, drug resistance mutations were detected in 24 (10%) maribavir recipients at 35–125 days (median, 56 days) after starting therapy, including in 12 of 14 who experienced a viral load rebound while on therapy. Ganciclovir resistance mutations developed in 6 (2.5%) valganciclovir recipients at 66–110 days (median, 90 days). One maribavir recipient developed a novel UL97 gene mutation (P-loop substitution G343A) that conferred strong maribavir and ganciclovir resistance in vitro. Viral clearance was confirmed in 17 (74%) of 23 patients with emergent maribavir resistance after retreatment with an alternative CMV antiviral drug.
Conclusions
After 3–8 weeks of therapy, maribavir resistance emerged earlier and more frequently than ganciclovir resistance but was usually treatable using alternative therapy. Clinical Trials Registration. NCT02927067 (AURORA).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA.
- Research and Development Service, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.
- Los Angeles Medical Center, University of California, Los Angeles, California, USA.
- Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
- Haematology Department, Henri Mondor Hôpital, Assistance Publique-Hopitaux de Paris, and Université Paris-Est-Créteil, Créteil, France.
- Department of Haematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
ORCID-Profile: Robin K Avery, Jo-Anne H Young
Förderung
- Takeda Development Center Americas, Inc
- VA
- US
- NCI NIH HHS
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
- Department of Veterans Affairs
Zitieren
APA
Chou, S., Winston, D. J., Avery, R. K., Cordonnier, C., Duarte, R. F., Haider, S., Maertens, J., Peggs, K. S., Solano, C., Young, J. H., Gu, J., Pocock, G., & Papanicolaou, G. A. (2025). Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae469
Vancouver
Chou S, Winston DJ, Avery RK, Cordonnier C, Duarte RF, Haider S, et al. Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae469
BibTeX
@article{Chou2025,
author = {Chou, Sunwen and Winston, Drew J and Avery, Robin K and Cordonnier, Catherine and Duarte, Rafael F and Haider, Shariq and Maertens, Johan and Peggs, Karl S and Solano, Carlos and Young, Jo-Anne H and Gu, Joan and Pocock, Ginger and Papanicolaou, Genovefa A},
title = {Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiae469}
}
EUVIMED